- Home
- GNTA vs RNTX Comparison
GNTA vs RNTX Comparison
Compare GNTA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | RNTX |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 35.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNTA | RNTX |
|---|---|---|
| Price | $1.01 | $1.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 3.0M | 153.3K |
| Earning Date | 03-24-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $1.02 |
| 52 Week High | $10.00 | $3.50 |
Technical Indicators
Market Signals| Indicator | GNTA | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 52.67 |
| Support Level | $1.26 | $1.12 |
| Resistance Level | $1.70 | $1.63 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 1.22 | 52.00 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.